TABLE 3.

Treatment of acute ischemic stroke in CRS‐ER

Year of publication	Test population (n)	TICI 2b or 3	P value	ICH	P value	mRS 0−2 at 3 months	P value	Death at 3 months	P value	Intrahospital mortality	p value
2018(Jung et al., 2018)	CRS (19) vs. LAA (105) vs. CE (205)	63.0% vs. 84.0% vs. 84.0%	0.060	N/A	N/A	16.0% vs. 54.0% vs. 44.0%	0.008	63.0% vs. 4.0% vs. 13.0%	<  0.001	N/A	N/A
2019(Sallustio et al., 2019)	CRS (24) vs. Non‐cancer (24)	76.9% vs. 61.5%	0.670	25.0% vs. 29.0%	1.000	25.0% vs. 29.1%	1.000	29.1% vs. 12.5%	0.280	8.3% vs. 4.1%	1.000
2019(D. Lee et al., 2019)	CRS (26) vs. Non‐cancer (227)	88.5% vs. 90.7%	0.723	57.7% vs. 38.7%	0.034	23.1% vs. 41.9%	0.064	30.8% vs. 8.8%	0.003	N/A	N/A
2020(Cho et al., 2020)	CRS (27) vs. Non‐cancer (351)	85.2% vs. 82.6%	0.800	44.4% vs. 32.8%	0.290	37.0% vs. 39.6%	0.840	33.3% vs. 8.2%	< 0.001	3.7% vs. 2.3%	0.490
2021(E. Lee et al., 2021)	CRS (34) vs. Non‐cancer (307)	79.4% vs. 86.7%	0.103	41.2% vs. 23.8%	0.037	N/A	N/A	26.5% vs. 6.8%	< 0.001	20.6% vs. 5.9%	0.009
2021(Ciolli et al., 2021)	CRS (14) vs. Non‐cancer (267)	71.0% vs. 78.0%	0.520	43.0% vs. 40.0%	1.000	21.0% vs. 44.0%	0.160	64.0% vs. 14.0%	< 0.010	43.0% vs. 6.0%	< 0.010

Abbreviations: ERT, endovascular recanalization therapy; ICH, intracranial hemorrhage.